All Stories

  1. Hepatitis A virus infection
  2. The History of Hepatitis A
  3. Hepatitis A and E – Differences and commonalities
  4. Prevention of Hepatitis A
  5. Viral envelope-specific antibodies in chronic hepatitis B virus infection
  6. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention
  7. Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups
  8. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review
  9. Acute hepatitis E virus in pregnant women in Israel and in other industrialized countries
  10. Hepatitis E virus in Israel: A nationwide retrospective study, from a non-endemic country
  11. Hepatotoxicity of herbal and dietary supplements: an update
  12. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine
  13. Focusing on the past, present, and future of hepatology
  14. Expanding the donor pool for liver transplant recipients using HBsAg positive grafts
  15. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine
  16. O-01: IL-10 receptor dependent signals regulate the generation and function of anti-inflammatory macrophages in mice and humans
  17. The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation
  18. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation
  19. Commonly Found Variations/Mutations in the HBsAg of Hepatitis B Virus in the Context of Effective Immunization Programs: Questionable Clinical and Public Health Significance
  20. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database
  21. The impact of chronic hepatitis C infection on the circadian clock and sleep
  22. Focus
  23. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study
  24. Hepatitis A Virus
  25. Focus
  26. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
  27. Focus
  28. Focus
  29. The State of Hepatitis B and C in the Mediterranean and Balkan Countries: Report from a Summit Conference
  30. Immunosuppression and HBV Reactivation
  31. Focus
  32. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
  33. Focus
  34. Focus
  35. Hepatitis B vaccines
  36. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma
  37. Focus
  38. Tracing hepatitis B virus to the 16th century in a Korean mummy
  39. Focus
  40. Focus
  41. Increased Prevalence of HBV Envelope Mutants in Taiwan: An Emerging Public Health Risk or a False Alarm?
  42. Breastmilk Hepatitis A Virus RNA in Nursing Mothers with Acute Hepatitis A Virus Infection
  43. Focus
  44. New doubts about preventing HAV superinfection in chronic HCV
  45. Focus
  46. 1030 TRANS-ARTERIAL CHEMO-EMBOLIZATION (TACE) IS SAFE AND EFFICIENT FOR ELDERLY PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM AN INTERNATIONAL META-DATABASE
  47. Hepatocellular carcinoma
  48. Focus
  49. Hepatitis A
  50. Focus
  51. Focus
  52. Focus
  53. Telaprevir for Retreatment of HCV Infection
  54. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
  55. Focus
  56. Focus
  57. Focus
  58. Focus
  59. Bacteremia and "Endotipsitis" following transjugular intrahepatic portosystemic shunting
  60. Focus
  61. Focus
  62. Focus
  63. Focus
  64. Focus
  65. The search for a new endpoint for antiviral prophylaxis in hepatitis B virus transplanted patients
  66. Focus
  67. Focus
  68. Focus
  69. Focus
  70. 591 TRANS ARTERIAL CHEMO-EMBOLIZATION (TACE) IS A SAFE AND EFFECTIVE TREATMENT FOR VERY ELDERLY PATIENTS WITH HEPATOCELLULR CARCINOMA (HCC)
  71. Focus
  72. Focus
  73. Endotipsitis-persistent infection of transjugular intrahepatic portosystemic shunt: pathogenesis, clinical features and management
  74. Strategies for Global Prevention of Hepatitis B Virus Infection
  75. Prof. Daniel Shouval
  76. 482 OUTCOME COMPARISON OF PERCUTANEOUS AND SURGICAL INTERVENTIONS IN PATIENTS WITH BUDD-CHIARI SYNDROME- A LONGITUDINAL SINGLE CENTER EXPERIENCE
  77. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
  78. EASL Clinical Practice Guidelines: Management of chronic hepatitis B
  79. Hepatitis B Vaccines
  80. 9.16 Chronic hepatitis and other liver disease
  81. Mononeuritis multiplex: a rare complication of acute hepatitis A
  82. The global impact of vaccination against hepatitis B: A historical overview
  83. Statements from the Taormina expert meeting on occult hepatitis B virus infection
  84. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology
  85. Herbalife revisited: Reply
  86. More reports of potential hepatotoxicity of Herbalife products: Reply
  87. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C
  88. Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries
  89. β-Glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: A novel adjuvant for HBV vaccination
  90. What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C?
  91. Hepatitis A and B vaccination and public health
  92. Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity
  93. Prevención de la reactivación de hepatitis B en pacientes inmunodeprimidos y con neoplasia
  94. Mathematical model of the antibody response to hepatitis B vaccines: Implications for reduced schedules
  95. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies
  96. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine
  97. Acute Hepatitis A Infection in Pregnancy Is Associated With High Rates of Gestational Complications and Preterm Labor
  98. 45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (study ETV-027)
  99. 733 Interim (week 12) phase 2b virological efficacy and safety results of albumin interferon Alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C infection
  100. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
  101. Graft-Versus-Host Disease and the Liver
  102. Adoptive transfer of immunity to HBV in liver transplant patients:A step forward toward the proof of concept for therapeutic vaccination or a transient immunologic phenomenon?
  103. P.082 Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)
  104. O.127 Phase 2b interim (week 12) results of albumin interferon alpha-2b combined with ribavirin in IFN-naïve, genotype 1 chronic hepatitis C infection
  105. The questionable role of immunization against hepatitis B in HBV infected liver transplant patients
  106. Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers
  107. Vaccination against hepatitis B and C: the state of the art
  108. Air transportation of patients with end-stage liver disease to distant liver transplantation centers
  109. Development of a scaled up liver device incorporating cryo-preserved pig liver micro-organs
  110. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation
  111. REDUCED INCIDENCE OF HYPERURICEMIA, GOUT, AND RENAL FAILURE FOLLOWING LIVER TRANSPLANTATION IN COMPARISON TO HEART TRANSPLANTATION: A LONG-TERM FOLLOW-UP STUDY
  112. Prevention of hepatitis C virus infection*
  113. Late cytomegalovirus disease following liver transplantation
  114. Liver micro-organs transcribe albumin and clotting factors and increase survival of 92% hepatectomized rats
  115. Hepatitis A booster vaccination: is there a need?
  116. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients
  117. Universal hepatitis A vaccination of young children is leading to disappearance of hepatitis A in adolescents and adults
  118. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon
  119. Late cytomegalovirus infection occurring two or more years following liver transplantation: a report of seven cases and review of the literature
  120. Hepatitis B vaccines
  121. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation
  122. Adoptive immune transfer as a therapeutic approach for persistent hepatitis B virus infection
  123. Late cytomegalovirus disease following liver transplantation
  124. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers
  125. Prognosis of Symptomatic Versus Asymptomatic Autoimmune Hepatitis
  126. HCC: What's the score
  127. Seroconversion after the addition of famciclovir therapy in a child with hepatitis B virus infection after liver transplantation who developed lamivudine resistance
  128. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties
  129. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors
  130. Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system
  131. Hepatitis C Virus Infection in Employees of a Large University Hospital in Israel
  132. Announcements
  133. Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine
  134. Hyper-IL-6 Gene Therapy Reverses Fulminant Hepatic Failure
  135. Prophylactic lamivudine therapy may prevent immunosuppressive induced HBV reactivation in chronic carriers
  136. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity
  137. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine
  138. Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients
  139. Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation
  140. TT Virus Infection in Israeli Patients with Fulminant Hepatic Failure
  141. Is universal vaccination against hepatitis B sufficient for control of HBV infection? Lessons from the immunization campaign in Italy
  142. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review
  143. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients
  144. Preclinical Evaluation of Two Human Anti–Hepatitis B Virus(HBV) Monoclonal Antibodies in the HBV-Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees
  145. Reply
  146. Transient Transmission of Hepatitis C Virus from Mothers to Newborns
  147. Human Interleukin-6 Facilitates Hepatitis B Virus Infection in Vitro and in Vivo
  148. Human liver micro-organs transcribe albumin and clotting factors in an in vivo perfusion model
  149. Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome
  150. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the Trimera mouse
  151. The trimera mouse system: A model for HCV infection and evaluation of antiviral drugs
  152. HBIG in patients liver transplanted with HBc positive donors
  153. Residual viral B particles at 10 years post trans-plantation in patients receiving long term anti-HBs immunoglobulins (HBIG)
  154. TT Virus Infection in Israeli Patients with Fulminant Hepatic Failure
  155. Interference of Antibody Production to Hepatitis B Surface Antigen in a Combination Hepatitis A/Hepatitis B Vaccine
  156. “Silent” presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection
  157. Hepatitis A vaccine for secondary hepatitis A infection
  158. Will transplantation of an hepatitis C–infected graft improve the outcome of liver transplantation in HCV patients?
  159. The role of ERCP in biliary complications after liver transplantation
  160. Comparison of immunogenicity of two hepatitis A vaccines — VAQTA® and HAVRIX® — in young adults
  161. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation
  162. Increased risk of exposure to hepatitis b infection among butchers sharing knives
  163. Antigen‐specific B and T cells in human/mouse radiation chimera following immunization in vivo
  164. The hepatitis B virus-trimera mouse: A model for human HBV infection and evaluation of anti-HBV therapeutic agents
  165. Chapter 9. A Professor of Phonetics (1919-21)
  166. Contents
  167. List of illustrations
  168. Chapter 8. The Outline
  169. Preface
  170. Appendix. Historical Background
  171. References
  172. Vaccines for prevention of viral hepatitis
  173. Psychological distress in patients with chronic, nonalcoholic, uncomplicated liver disease
  174. Liver Transplantation Across the ABO Barrier: The Role of Plasmapheresis
  175. Octreotide in hepatocellular carcinoma
  176. The HBV trimera mouse: a model for human HBV infection and evaluation of anti-viral agents
  177. Natural course of de novo hepatitis B virus infection in liver transplant recipients
  178. Hepatitis-C-associated cryoglobulinemia after liver transplantation
  179. Should hepatitis B immunoglobulin therapy be discontinued after HBV reinfection following liver transplantation?
  180. Natural course of HCV viremia following liver transplantation and clinical course of reinfection
  181. Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen
  182. Comparison of methods for extraction of nucleic acid from hemolytic serum for PCR amplification of hepatitis B virus DNA sequences
  183. Hepatitis A Prophylaxis
  184. Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation
  185. Need for liver transplantation
  186. Esophageal Malignancy after Liver Transplantation in a Patient with Barrett's Esophagus
  187. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report
  188. Adoptive transfer of immunity to hepatitis B: development of the concept and evolution of the research project for targeted immunotherapy against hepatic cells which express a viral antigen
  189. The need for liver transplantation: a nationwide estimate based on consensus review
  190. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus
  191. Hepatitis C Virus Viremia in SCID -> BNX Mouse Chimera
  192. Hepatitis A virus and polymerase chain reaction amplification
  193. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma
  194. Correction of ?-glucuronidase deficiency in mice by intrasplenic transplantation of isolated hepatocytes
  195. Aorto-atrial fistula following internal jugular vein catheterization
  196. Immunization against Hepatitis B through Adoptive Transfer of Immunity
  197. Exposure to hepatitis B and C and to HTLV‐1 and 2 among Israeli drug abusers in Jerusalem
  198. Round Table Discussion
  199. A Double Virus‐Inactivated Factor VIII Preparation: Validation and Biochemical Characteristics
  200. Hepatitis A Virus Infection among the Hemophilia Population at the Bonn Hemophilia Center
  201. Inactivation of Hepatitis A Virus by Pasteurization and Elimination of Picornaviruses during Manufacture of Factor VIII Concentrate
  202. Sequence Variability of Hepatitis A Virus and Factor VIII Associated Hepatitis A Infections in Hemophilia Patients in Europe: An Update
  203. A New Vaccine for the Prevention of Hepatitis A: Summary of a Satellite Symposium
  204. Adoptive Transfer of Immunity to Hepatitis B Through Bone Marrow Transplantation from Immunized Donors
  205. Immunogenicity of a Mammalian Cell-derived Recombinant Hepatitis B Vaccine Containing Pre S2 and Pre S1 Antigens: A Preliminary Report
  206. Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes
  207. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines
  208. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation
  209. Sclerosing cholangitis associated with Crohn's disease and autoimmune haemolytic anaemia
  210. IgA deficiency associated with chronic hepatitis C virus infection. A cause or an effect?
  211. Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors
  212. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor
  213. Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors
  214. Foreword
  215. Excessive Hepatitis-B Surface Antigen Production After Corticosteroids and the Development of Immunoblastic Lymphoma
  216. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin
  217. Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial
  218. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview
  219. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis
  220. A finger-stick assay for determination of immunity to hepatitis A: a preliminary report
  221. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.
  222. SEROLOGICAL AND MOLECULAR ANALYSIS OF HLA IN ISRAELI PRIMARY SCLEROSING CHOLANGITIS PATIENTS
  223. Liver Failure and the Sea-Blue Histocyte/Adult Niemann—Pick Disease
  224. A Controlled Trial of a Formalin-Inactivated Hepatitis A Vaccine in Healthy Children
  225. Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice
  226. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines
  227. Relapsing Hepatitis A Review of 14 Cases and Literature Survey
  228. p53 mutation in hepatocellular carcinoma after aflatoxin exposure
  229. Prevalence of HBsAg carriers in native and immigrant pregnant female populations in Israel and passive/active vaccination against HBV of newborns at risk
  230. Localized primary sclerosing cholangitis mimicking a cholecystectomy stricture relieved by an endoprosthesis
  231. Reply
  232. A conjugate of 5-fluorouridine-poly(L-lysine) and an antibody reactive with human colon carcinoma
  233. Postpartum Budd-Chiari syndrome with prolongedhypercoagulability state
  234. The effect of anti-α-fetoprotein-adriamycin conjugate on a human hepatoma
  235. Hepatitis during measles in young adults: Possible role of antipyretic drugs
  236. Detection of hepatitis a virus rna in serum from patients with acute hepatitis
  237. A Common-Source Outbreak of Fulminant Hepatitis B in a Hospital
  238. Radioimmunolocation of Hepatic and Pulmonary Metastasis of Human Colon Adenocarcinoma
  239. In Vivo expression of two novel tumor-associated antigens and their use in immunolocalization of human hepatocellular carcinoma
  240. Improvement of Immune-Complex Nephritis Associated with Hepatitis B Surface Antigen Excess
  241. Measles
  242. Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens.
  243. An acupuncture-associated outbreak of hepatitis B in Jerusalem
  244. Sublines of the Burkitt line Daudi, selected on the basis of reactivity with soybean agglutinin, differ in tumorigenicity in athymic mice
  245. Production of Erythropoietin by an Established Human Renal Carcinoma Cell Line: In Vitro and In Vivo Studies
  246. Comparative morphology and tumourigenicity of human hepatocellular carcinoma cell lines in athymic rats and mice
  247. Clofibrate does not induce peroxisomal proliferation in human hepatoma cell lines PLC/PRF/5 and SK-HEP-1
  248. Recombinant alpha interferon suppresses HBV enhancer activity
  249. Detection of alpha-foetoprotein messenger RNA in human hepatocellular carcinoma and hepatoblastoma tissue
  250. Continuous production of erythropoietin by an established human renal carcinoma cell line: development of the cell line.
  251. Conjugates between monoclonal antibodies to HBsAg and cytosine arabinoside
  252. Papular Acrodermatitis of Childhood Associated with Hepatitis A Virus Infection
  253. Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal antibodies.
  254. Human hepatoma-associated cell surface antigen: Identification and characterization by means of monoclonal antibodies
  255. Conservation from rat to human of cytosolic phosphoenolpyruvate carboxykinase and the control of its gene expression
  256. Development of a novel Clq immunoadsorbent for removal of circulating immunecomplexes: Quantitative isolation of hepatitis B virus surface antigen and immunecomplexes
  257. Detection and characterization of hepatitis B virus DNA in serum of HBe antigen-negative HBsAg carriers
  258. Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus
  259. Aortic Insufficiency Unmasked by a Peritoneovenous Shunt
  260. Immunotherapy in nude mice of human hepatoma using monoclonal antibodies against hepatitis B virus
  261. Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen.
  262. Laboratory Stigmata of Connective Tissue Disorders in Asymptomatic Carriers of Hepatitis B Virus
  263. Integration of Hepatitis B Virus DNA into the Genome of Liver Cells in Chronic Liver Disease and Hepatocellular Carcinoma
  264. Chronic hepatitis in chimpanzee carriers of hepatitis B virus: morphologic, immunologic, and viral DNA studies.
  265. Identification of integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-producing human hepatocellular carcinoma cell line
  266. Premature Appearance of Hepatic Phosphoenolpyruvate Carboxykinase in Fetal Rats, Not Mediated by Adenosine 3': 5'-Monophosphate
  267. EFFECT OF CO-TRIMOXAZOLE ON NORMAL CREATININE CLEARANCE
  268. Subtypes of Hepatitis B Surface Antigen in Native-Born and Immigrant Israelis